Top MarketRank™ StocksTop MarketRank™NASDAQ:HALO Halozyme Therapeutics (HALO) Stock Price, News & Analysis $54.13 +0.28 (+0.52%) (As of 10/8/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Halozyme Therapeutics Stock (NASDAQ:HALO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Halozyme Therapeutics alerts:Sign Up Key Stats Today's Range$53.25▼$54.8250-Day Range$51.94▼$64.4252-Week Range$32.83▼$65.53Volume2.10 million shsAverage Volume1.28 million shsMarket Capitalization$6.89 billionP/E Ratio22.37Dividend YieldN/APrice Target$60.44Consensus RatingModerate Buy Company OverviewHalozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Read More… [SHOCKING] Crypto Document Leak… (Ad)The crypto market waits for no one. And my team of experts and I believe that a BIG move is right around the corner. That's why we're offering you instant access to the game-changing book that's transforming average investors into massive crypto successes.Download your digital copy now Halozyme Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks98th Percentile Overall ScoreHALO MarketRank™: Halozyme Therapeutics scored higher than 98% of companies evaluated by MarketBeat, and ranked 14th out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingHalozyme Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageHalozyme Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Halozyme Therapeutics' stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth21.02% Earnings GrowthEarnings for Halozyme Therapeutics are expected to grow by 21.02% in the coming year, from $3.71 to $4.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Halozyme Therapeutics is 22.37, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 121.56.Price to Earnings Ratio vs. SectorThe P/E ratio of Halozyme Therapeutics is 22.37, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 126.56.Price to Earnings Growth RatioHalozyme Therapeutics has a PEG Ratio of 0.56. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHalozyme Therapeutics has a P/B Ratio of 85.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Halozyme Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.69% of the float of Halozyme Therapeutics has been sold short.Short Interest Ratio / Days to CoverHalozyme Therapeutics has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Halozyme Therapeutics has recently decreased by 3.98%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHalozyme Therapeutics does not currently pay a dividend.Dividend GrowthHalozyme Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.12 Percentage of Shares Shorted7.69% of the float of Halozyme Therapeutics has been sold short.Short Interest Ratio / Days to CoverHalozyme Therapeutics has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Halozyme Therapeutics has recently decreased by 3.98%, indicating that investor sentiment is improving. News and Social Media2.5 / 5News Sentiment0.58 News SentimentHalozyme Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Halozyme Therapeutics this week, compared to 7 articles on an average week.Search InterestOnly 21 people have searched for HALO on MarketBeat in the last 30 days. This is a decrease of -16% compared to the previous 30 days.MarketBeat Follows15 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,932,284.00 in company stock.Percentage Held by InsidersOnly 2.40% of the stock of Halozyme Therapeutics is held by insiders.Percentage Held by Institutions97.79% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Halozyme Therapeutics' insider trading history. Receive HALO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HALO Stock News HeadlinesHalozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley Sells 10,000 SharesSeptember 27, 2024 | insidertrades.comMichael J. Labarre Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) StockSeptember 19, 2024 | insidertrades.com[SHOCKING] Crypto Document Leak…The crypto market waits for no one. And my team of experts and I believe that a BIG move is right around the corner. That's why we're offering you instant access to the game-changing book that's transforming average investors into massive crypto successes.October 8, 2024 | Crypto 101 Media (Ad)Helen Torley Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) StockSeptember 14, 2024 | insidertrades.comWells Fargo Downgrades Halozyme Therapeutics (HALO) Due to Limited UpsideOctober 8 at 4:12 AM | gurufocus.comHalozyme Therapeutics (NASDAQ:HALO) Downgraded by Wells Fargo & Company to Equal WeightOctober 8 at 4:07 AM | americanbankingnews.comAnalysts Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) Target Price at $60.00October 8 at 2:25 AM | americanbankingnews.comHalozyme Therapeutics shares fall as Wells Fargo cuts rating to equal weightOctober 7 at 4:28 PM | msn.comSee More Headlines HALO Stock Analysis - Frequently Asked Questions How have HALO shares performed this year? Halozyme Therapeutics' stock was trading at $36.96 on January 1st, 2024. Since then, HALO stock has increased by 46.5% and is now trading at $54.13. View the best growth stocks for 2024 here. How were Halozyme Therapeutics' earnings last quarter? Halozyme Therapeutics, Inc. (NASDAQ:HALO) posted its quarterly earnings data on Tuesday, August, 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.73 by $0.18. The firm's revenue was up 4.7% on a year-over-year basis. Does Halozyme Therapeutics have any subsidiaries? Halozyme Therapeutics subsidiaries include Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH. Who are Halozyme Therapeutics' major shareholders? Halozyme Therapeutics' top institutional investors include Handelsbanken Fonder AB (1.55%), Brookstone Capital Management (0.05%), FCF Advisors LLC (0.03%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Helen Torley, Michael J Labarre, Matthew L Posard, Jeffrey William Henderson, James M Daly, Nicole Labrosse and Connie Matsui. View institutional ownership trends. How do I buy shares of Halozyme Therapeutics? Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Halozyme Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Halozyme Therapeutics investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD) and Athabasca Oil (ATH). Company Calendar Last Earnings8/06/2024Today10/08/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:HALO CUSIP40637H10 CIK1159036 Webwww.halozyme.com Phone858-794-8889Fax858-704-8311Employees390Year Founded1998Price Target and Rating Average Stock Price Target$60.44 High Stock Price Target$71.00 Low Stock Price Target$49.00 Potential Upside/Downside+11.7%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$2.42 Trailing P/E Ratio22.37 Forward P/E Ratio14.59 P/E Growth0.56Net Income$281.59 million Net Margins38.62% Pretax Margin47.72% Return on Equity195.80% Return on Assets21.07% Debt Debt-to-Equity Ratio5.19 Current Ratio7.41 Quick Ratio6.21 Sales & Book Value Annual Sales$873.30 million Price / Sales7.89 Cash Flow$2.94 per share Price / Cash Flow18.42 Book Value$0.63 per share Price / Book85.92Miscellaneous Outstanding Shares127,274,000Free Float124,219,000Market Cap$6.89 billion OptionableOptionable Beta1.27 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:HALO) was last updated on 10/8/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
